Precision BioSciences Announces Return Of Programs And Conclusion Of Collaboration With Prevail Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences (DTIL) has concluded its collaboration with Prevail Therapeutics, regaining control of three programs. The collaboration demonstrated the efficacy of ARCUS for gene excision and insertion. DTIL plans to continue developing these programs independently or with new partners. The company's key clinical priorities in Hepatitis B and Primary Mitochondrial Myopathy, along with its financial runway until the second half of 2026, remain unaffected.
April 16, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precision BioSciences regains control of three programs from Prevail Therapeutics, planning to continue development, with key projects and financial runway unaffected.
Regaining control of these programs allows DTIL to potentially accelerate development and seek strategic partnerships, which could positively impact its stock. The unaffected financial runway and focus on key clinical priorities suggest a stable and promising outlook, likely to be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90